iPharmaTrials 

 

Concussion Sequelae Boost Alzheimer’s Risk

| January 20, 2022 | 0 comments
Post-traumatic amnesia (PTA) and chronic vascular lesions caused by traumatic brain injury (TBI) is tied to an increased risk of subsequent Alzheimer’s disease (AD), new research suggests. Results from a case-controlled retrospective study showed the presence of PTA or of vascular lesions on neuroimaging in patients with TBI was significantly associated with up to an
iPharmaTrials

5 Reasons to See an Accident Injury Doctor

| January 20, 2022 | 0 comments
Car accidents are often upsetting and the aftermath can be chaotic. If you’ve had a serious car accident, you may be unsure how to proceed. Whether or not you are experiencing car accident injuries with acute symptoms, it’s unlikely that anyone ever prepared you for such a traumatic event. After you’ve visited the hospital for
iPharmaTrials

Scientists identify antibodies that can neutralize omicron

| January 6, 2022 | 0 comments
An international team of scientists have identified antibodies that neutralize omicron and other SARS-CoV-2 variants. These antibodies target areas of the virus spike protein that remain essentially unchanged as the viruses mutate. By identifying the targets of these “broadly neutralizing” antibodies on the spike protein, it might be possible to design vaccines and antibody treatments
iPharmaTrials, News, Press Releases

Abbott receives FDA 510(K) clearance for the first rapid handheld blood test for concussions

| September 8, 2021 | 0 comments
-The test to help evaluate mild traumatic brain injury (TBI), commonly known as concussion, produces a result within 15 minutes after a plasma sample is inserted and will run on Abbott’s i-STAT™ Alinity™ handheld device – Having a blood test available could help eliminate wait time in the emergency room and could reduce the number
iPharmaTrials, Press Releases
Stoned drivers are a lot safer than drunk ones, new federal data shows

Stoned drivers are a lot safer than drunk ones, new federal data shows

| June 21, 2019 | 0 comments
A new study from the National Highway Traffic Safety Administration finds that drivers who use marijuana are at a significantly lower risk for a crash than drivers who use alcohol. And after adjusting for age, gender, race and alcohol use, drivers who tested positive for marijuana were no more likely to crash than who had
driving, medical marijuana
iPharmaTrials, News, Press Releases
Breaking News! Cannabis and Psychosis: Triangulating the Evidence

Breaking News! Cannabis and Psychosis: Triangulating the Evidence

| May 7, 2019 | 0 comments
Disentangling causality where complex and confounded behaviours might be impacting on even more complex mental health outcomes is notoriously challenging, and requires tackling the question in a number of different ways to triangulate the evidence. Although observational epidemiology and experimental studies are broadly consistent in indicating a link between heavy cannabis use and risk of
iPharmaTrials, News
Driver in Limousine Crash had Marijuana in System

Driver in Limousine Crash had Marijuana in System

| April 7, 2019 | 0 comments
Traces of anti-seizure medicine also were found in post-mortem tests SCHOHARIE — The driver of a Ford Excursion limousine that crashed in Schoharie last October, killing 20 people, had a “significant” amount of marijuana in his system at the time he died, according to two people with knowledge of the driver’s post-mortem toxicology report. The
anti-seizure medicine
iPharmaTrials, News, Press Releases
Going to get your favorite CBD-Latte in New York?

Going to get your favorite CBD-Latte in New York?

| February 10, 2019 | 0 comments
Going to get your favorite CBD-Latte in New York? Best stay home and make it yourself as the City’s Health Department has classified CBD as an illegal additive in any/all Food & Beverages as of early February. This came to light following news that several restaurants including Fat Cat Kitchen in Gramercy Park were visited
iPharmaTrials
Health Effects of Cannabis and Cannabinoids

Health Effects of Cannabis and Cannabinoids

| January 14, 2019 | 0 comments
In the report The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research, an expert, ad hoc committee of the National Academies of Sciences, Engineering, and Medicine presents nearly 100 conclusions related to the health effects of cannabis and cannabinoid use. The committee developed standard language to categorize the
Cannabinoids, Cannabis
iPharmaTrials, News, Press Releases

Cannabinoid (CB1) Receptor Activation Inhibits Trigeminovascular Neurons

| July 14, 2018 | 0 comments
Simon Akerman, Philip R. Holland, and Peter J. Goadsby Headache Group, Institute of Neurology and the National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom Received April 29, 2006; accepted October 2, 2006 ABSTRACT Migraine is a common and disabling neurological disorder that involves activation or the perception of activation of the trigeminovascular
migraine
iPharmaTrials, Press Releases

Resources

 

– Krishna’s Corner
– Krishna’s Blog
– Store

iPT Tweets

 

News

 

iPHARMA TRIALS

 

New York, USA
Telephone : 718-332-7878
rkrishna -AT- ipharmatrials.com
.. replace -AT- with @

United Kingdom
The Studio/East Batterlaw Farm
Seaham SR7 8RP

Corporation Registration Address:
330 Thornton Road Englewood NJ 07631